- EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
- Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
- Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
- Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
- Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
- Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
- Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
- Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
More ▼
Key statistics
On Friday, Crinetics Pharmaceuticals Inc (CRNX:NSQ) closed at 43.83, -18.38% below its 52-week high of 53.70, set on May 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 44.02 |
---|---|
High | 44.46 |
Low | 43.71 |
Bid | 43.20 |
Offer | 45.00 |
Previous close | 44.20 |
Average volume | 1.45m |
---|---|
Shares outstanding | 78.86m |
Free float | 75.69m |
P/E (TTM) | -- |
Market cap | 3.49bn USD |
EPS (TTM) | -3.77 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 21:15 BST.
More ▼